A1 Journal article – refereed
Brain neurokinin-1 receptor availability in never-medicated patients with major depression - A pilot study




List of Authors: Mikko Nyman, Olli Eskola, Jaana Kajander, Riitta Jokinen, Jukka Penttinen, Tomi Karjalainen, Lauri Nummenmaa, Jussi Hirvonen, Donald Burns, Richard Hargreaves, Olof Solin, Jarmo Hietala
Publisher: ELSEVIER SCIENCE BV
Publication year: 2019
Journal: Journal of Affective Disorders
Journal name in source: JOURNAL OF AFFECTIVE DISORDERS
Journal acronym: J AFFECT DISORDERS
Volume number: 242
Number of pages: 7
ISSN: 0165-0327
eISSN: 1573-2517

Abstract
Background: Neurotransmitter substance P (SP) and its preferred neurokinin-1 receptor (NK1R) have been implicated in the treatment of affective and addiction disorders. Despite promising preclinical data on anti-depressant action, the clinical trials of NK1R antagonists in major depression have been disappointing. There are no direct in vivo imaging studies on NK1R characteristics in patients with a major depressive disorder (MDD).Methods: In this cross-sectional case-control study, we recruited nine never-medicated patients with moderate to severe MDD and nine matched healthy controls. NK1R availability (NK1R binding potential, BPND) was measured with in vivo 3-D positron emission tomography and a specific NK1 receptor tracer [18F] SPA-RQ. Clinical symptoms were assessed with the 17-item Hamilton Rating Scale for Depression (HAM-D17).Results: NK1R-BPND did not differ statistically significantly between patients with MDD and healthy controls. HAM-D17 total scores (range 21-32) correlated positively with NK1R-BPND in cortical and limbic areas. HAMD17 subscale score for anxiety symptoms correlated positively with NK1R-BPND in specific brain areas implicated in fear and anxiety.Limitations: Small sample size. Low variability in the clinical HAM-D subscale ratings may affect the observed correlations.Conclusions: Our preliminary results do not support a different baseline expression of NK1Rs in a representative sample of never-medicated patients with MDD during a current moderate/severe depressive episode. The modulatory effect of NK1Rs on affective symptoms is in line with early positive results on antidepressant action of NK1 antagonists. However, the effect is likely to be too weak for treatment of MDD with NK1R antagonists alone in clinical practice.

Last updated on 2019-21-08 at 21:31